Navigation Links
3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Date:11/10/2012

th IC50s in the 5-50nM range;
  • Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN;
  • Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and
  • Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors.
  • 3-V's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties.  The company has filed multiple worldwide patent applications covering these inhibitors.  3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.

    Data describing 3-V's FASN inhibitor preclinical activity will be presented by Dr. Kemble during Sunday's HCV Therapy: Preclinical and Early Clinical Development parallel session at 5:30 pm in a talk titled: "Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid Synthase" (Abstract #88).  A poster, "TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained Host-Target Inhibition in Vivo" (Abstract #1876), describing mechanism and activity for one of 3-V's compounds will be presented on Tuesday, November 13 during the HCV Therapy: Preclinical and Early Clinical Development poster session from 8:00 a.m. to 12:00 p.m.

    About FASN
    FASN is a cellular enzyme implicated in HCV replication and several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and ha
    '/>"/>

    SOURCE 3-V Biosciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
    2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
    3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
    4. Neurocrine Biosciences Reports First Quarter 2012 Results
    5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
    6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
    8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
    9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
    10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
    11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
    (Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
    (Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
    Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
    ... States Food and Drug Administration ("FDA") said its primary results ... risk of blood clots for women who use drospirenone-containing birth ... safety of Yaz and Yasmin is the subject of approximately ... Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex ...
    ... BEACH, Calif., Sept. 27, 2011 For the third ... InformationWeek 500 annual listing of the nation,s most innovative ... honored for development and implementation of its Treatment ... communities real-time cost estimates specific to their coverage plan, ...
    Cached Medicine Technology:FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 3
    (Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
    (Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
    (Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
    (Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
    Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
    ... , THURSDAY, Dec. 1 (HealthDay News) -- Posting ... processing plants on the Internet so it can be viewed ... report released Wednesday. The report is from the National ... advice on challenges facing the United States and the world. ...
    ... in the levels of two proteins involved in folding, ... destructive brain plaque found in Alzheimer,s disease, researchers report. ... specific positions to unleash their functions. When levels are ... normally dormant BACE1, a protein responsible for beta amyloid ...
    ... MD, a fourth-year resident in clinical and anatomic ... the highly coveted Resident Leadership Representative Award from ... demonstrating leadership and promoting ASCP membership and resident ... team led by Dr. Martin Kroll, won the ...
    ... (EGCG)a flavonoid found in green teainhibits the hepatitis C ... in the December issue of Hepatology , a ... Association for the Study of Liver Diseases, suggest that ... reinfection following liver transplantation. HCV infection can ...
    ... on chromosomes in human cervical cancer cells disrupts DNA ... and kills them more quickly, according to a study ... to like see their laboratory findings published in ... safer, more effective combination therapies for hard-to-treat pediatric brain ...
    ... December 1, 2011 -- Only 21 percent of surveyed medical ... when and when not to wash their hands in the ... issue of the American Journal of Infection Control , ... in Infection Control and Epidemiology. Three researchers from ...
    Cached Medicine News:Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 3Health News:2 out of 3 medical students do not know when to wash their hands 2
    ... most other EMR,systems require you ... is the only,electronic patient charting,solution ... orthopaedic,workflow. Created around,five specific criteria ... clinic,OrthoPad allows you to see,more ...
    The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
    The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
    ... EMS provides service to companies in many different ... and restaurants.There are no hidden charges at EMS ... and service are among the lowest in the ... of services ranging from MasterCard/Visa processing to Debit ...
    Medicine Products: